-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NC-2400 in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NC-2400 in Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NC-2400 in Dyslipidemia Drug Details: NC-2400 (CER-002) is under development for the treatment...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Product Insights
NewArteriosclerosis – Drugs In Development, 2024
Empower your strategies with our Arteriosclerosis – Drugs In Development, 2024 report and make more profitable business decisions. Arteriosclerosis refers to the thickening and hardening of arteries due to plaque buildup, limiting blood flow. Atherosclerosis, a common form, involves cholesterol and other substances accumulating in arterial walls, narrowing them. This condition heightens the risk of heart disease, stroke, and peripheral artery disease. Factors like high blood pressure, cholesterol, smoking, diabetes, and obesity contribute. Management involves lifestyle changes—such as a healthy diet...
-
Product Insights
NewAtherosclerosis – Drugs In Development, 2024
Empower your strategies with our Atherosclerosis – Drugs In Development, 2024 report and make more profitable business decisions. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive buildup of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina); pain in the leg, arm, and anywhere else that an artery is blocked; shortness of breath;...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewSepsis – Drugs In Development, 2024
Empower your strategies with our Sepsis – Drugs In Development, 2024 report and make more profitable business decisions. Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function, and abdominal pain....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NC-2400
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NC-2400 Drug Details NC-2400 (CER-002) is under development for the treatment of dyslipidemia with...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CER-209
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CER-209 Drug Details CER-209 is under development for the treatment of dyslipidemia with low...
-
Product Insights
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atherosclerosis (or arteriosclerotic vascular disease) may occur with symptoms including chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation. The Atherosclerosis pipeline drugs market research report outlays comprehensive information on the Atherosclerosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...